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provided evidence for a transmission of severe or even fatal 
disease. In addition, available epidemiological data do not 
indicate a transmissibility of AD or PD between humans. 
The findings published so far on the effects of experimen-
tally transmitted AD- or PD-associated protein seeds do not 
suggest specific precautionary measures in the context of 
hemotherapy, but call for vigilance in transfusion medicine 
and other medical areas.
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Introduction
Many neurodegenerative diseases such as Alzheimer’s dis-
ease (AD), Parkinson’s disease (PD), Huntington’s disease, 
amyotrophic lateral sclerosis, or frontotemporal dementias 
share as a defining neuropathological feature the aggrega-
tion and deposition of misfolded endogenous proteins in 
the central nervous system (CNS). Although their amino 
acid sequences and native folds differ from each other, 
these disease-associated proteins form extracellular amy-
loid deposits or intracellular amyloid-like inclusions with 
common structural characteristics. Amyloid or amyloid-
like protein deposits typically show a fibrillar morphol-
ogy and an ordered “cross-β” assembly of the aggregated 
proteins. Comprehensive evidence suggests that a general 
mechanism of “nucleated growth” underlies the aggrega-
tion of endogenous proteins in the neurodegenerative dis-
eases mentioned above (for a review see [16]).
A similar mechanism is thought to govern the self-
propagation and cerebral deposition of amyloid-like beta-
sheet-rich aggregates of misfolded prion protein (PrP) in 
Abstract The misfolding and aggregation of endogenous 
proteins in the central nervous system is a neuropathologi-
cal hallmark of Alzheimer’s disease (AD), Parkinson’s dis-
ease (PD), as well as prion diseases. A molecular mecha-
nism referred to as “nucleation-dependent aggregation” is 
thought to underlie this neuropathological phenomenon. 
According to this concept, disease-associated protein par-
ticles act as nuclei, or seeds, that recruit cellular proteins 
and incorporate them, in a misfolded form, into their 
growing aggregate structure. Experimental studies have 
shown that the aggregation of the AD-associated proteins 
amyloid-β (Aβ) and tau, and of the PD-associated protein 
α-synuclein, can be stimulated in laboratory animal mod-
els by intracerebral (i.c.) injection of inocula containing 
aggregated species of the respective proteins. This has 
raised the question of whether AD or PD can be transmit-
ted, like certain human prion diseases, between individuals 
by self-propagating protein particles potentially present on 
medical instruments or in blood or blood products. While 
the i.c. injection of inocula containing AD- or PD-associ-
ated protein aggregates was found to cause neuronal dam-
age and clinical abnormalities (e.g., motor impairments) in 
some animal models, none of the studies published so far 
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transmissible spongiform encephalopathies (TSEs) [20, 
87]. Yet, these fatal neurodegenerative diseases in animals 
[e.g., scrapie, bovine spongiform encephalopathy (BSE)] 
and humans [e.g., Creutzfeldt–Jakob disease (CJD)] were 
considered for many years unique. This is because they 
are caused, and can be transmitted between individuals, 
by unconventional pathogens devoid of coding nucleic 
acids designated as “proteinaceous infectious particles”, 
or “prions” [71, 72]. However, during the past few years 
an increasing number of prion-like phenomena have been 
detected in the context of AD, PD, and other non-prion 
neurodegenerative diseases [12, 32, 43, 52]. This has 
raised concerns that the transmission of pathological pro-
tein aggregates from common neurodegenerative diseases 
(which are generally presumed to be non-transmissible) 
may possibly pose a previously unrecognized risk to patient 
safety, e.g., in surgery or transfusion medicine.
To address this topical question for the two most fre-
quent neurodegenerative disorders, AD and PD, this article 
reviews similarities and differences shown by pathological 
protein particles of these diseases in comparison to prions. 
After a brief introduction to prions and prion diseases, we 
provide an overview of animal experiments and epide-
miological studies that have examined the transmission of 
protein aggregation, neurodegeneration or clinical disease 
between individuals by AD- or PD-associated protein par-
ticles. Finally, we discuss the results from these studies 
with respect to both implications for transmission risks and 
practical conclusions for transfusion medicine and other 
medical areas.
The example of prions and prion diseases
Molecular basis of prion formation, replication 
and transmission
Human TSEs, or prion diseases, occur in idiopathic, 
hereditary and acquired forms as exemplified by spo-
radic, familial and variant Creutzfeldt–Jakob disease 
(sCJD, fCJD and vCJD), respectively [73]. According to 
current knowledge, all of these diseases are caused and 
are transmissible by proteinaceous infectious particles 
(prions) that accumulate in the brain [71, 72, 87]. Prions 
are thought to be essentially composed of misfolded and 
aggregated conformational isomers of the cellular prion 
protein (PrPC), referred to as PrPSc or PrPTSE [10, 72] 
(the acronym PrPTSE will be used in this article). While 
PrPC contains a high proportion of α-helical structure 
and only 3 % β-sheets, PrPTSE has a profoundly different, 
amyloid-like conformation that is substantially made up 
of β-sheets and exhibits a markedly reduced amount of 
α-helical structure [15, 29, 66].
The prevailing mechanistic model of prion replication 
involves nucleation-dependent aggregation of the prion 
protein (Fig. 1) [20, 35, 87]. According to this concept, 
prions of sporadic or familial CJD are thought to be ini-
tially formed by a self-assembly of PrP monomers that 
occurs spontaneously (sCJD) or in association with sto-
chastic (sCJD) or inherited (fCJD) amino acid exchanges 
in the prion protein which facilitate a structural PrP con-
version. The de novo aggregation, or nucleation, of PrP 
constitutes a high kinetic reaction barrier [20, 35]. Thus, 
nucleation is considered as a slow and rate-determining 
step in the genesis of sporadic and hereditary prion dis-
eases. However, once PrP nuclei have been formed the 
conversion of PrPC to PrPTSE is no longer kinetically 
inhibited. Then, the growth of PrP aggregates proceeds 
swiftly by the successive association of further PrP 
molecules, in an aberrant folding structure that repro-
duces the conformation of the PrPTSE template, with the 
nucleus. This mechanism of nucleated growth is strongly 
reminiscent of the acceleration of crystallization by 
“seeding” (i.e., the addition of preformed “seeds” to a 
salt or protein solution). Accordingly, “PrP seeding” 
provides a straightforward explanation for why prions 
are agents that can transmit the misfolding and aggrega-
tion of PrP between individuals: Upon introduction into 
a new host they simply act as exogenous proteinaceous 
seeds which bypass the slow nucleation step of PrP con-
version. When PrPTSE aggregates fragment into smaller 
units this increases the number of prion protein particles 
with seeding-active growth surfaces. Thus, while the de 
novo formation of prions depends on nucleation, prion 
replication is mediated by an alternating growth and 
fragmentation of PrPTSE aggregates. In seeded PrPC to 
PrPTSE conversion, the conformation of the PrPTSE tem-
plate is typically reproduced with high fidelity. On this 
basis, phenotypically distinct prion agents that are made 
up of PrP with an identical amino acid and referred to 
as prion “types” or “strains” can exist and propagate in 
vivo in the form of different PrP conformers [14, 45, 94].
Based on their replication mechanism prions can 
transmit misfolding and aggregation of PrP (i) at the 
molecular level, (ii) within or at the surface of cells, 
(iii) from one cell to another, (iv) in and between tissues 
[e.g., along neuroanatomical pathways in the peripheral 
and central nervous system (PNS, CNS), or between 
the lymphoreticular system and the PNS], and (v) also 
between individuals. The formation and/or replica-
tion of prions trigger pathogenic processes that are still 
poorly understood and cause neuronal degeneration in 
the brain. This results in neurological or mental symp-
toms and eventually fatal disease in sporadic, hereditary 
and acquired TSEs. Prions are able to transmit TSEs 
between animals, from animal to man (or vice versa), 
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and between humans. Thus, they are genuinely infec-
tious agents.
Notably, prion replication by the described propagation 
of PrPTSE seeds is in principle indefinitely self-perpetuat-
ing. This holds true in cell-free conversion assays [6, 13, 
93], cell assays [21, 48] and bioassays using transgenic or 
wild-type animals [31, 47] as evidenced by sustained PrPC 
to PrPTSE conversion and/or replication of infectivity in 
multiple serial passages in which the original seeds were 
gradually diluted out.
Iatrogenic transmission of human prions: occurrence 
and prevention
A total of more than 450 cases of iatrogenic CJD have 
occurred worldwide after application of cadaver-derived 
human growth hormone (c-hGH) or gonadotrophin, trans-
plantation of dura mater or cornea, and neurosurgery or 
EEG recording using invasive medical devices [11]. In 
addition, iatrogenic transmission of vCJD by blood trans-
fusion is presumed for three clinically diseased recipients 
[36, 53, 95] and for one asymptomatic recipient [68] of 
non-leucodepleted erythrocytes. Furthermore, asympto-
matic vCJD was diagnosed in a patient with hemophilia 
who had received factor VIII concentrate prepared from 
plasma pools that included donations from a vCJD-infected 
donor [67].
The BSE epidemic and resulting emergence of vCJD 
in the United Kingdom, and the subsequent occurrence 
of these novel TSEs in other countries, have substantially 
increased awareness of the zoonotic and iatrogenic risk 
potential of proteinaceous infectious particles. Together 
with the lessons learned from iatrogenic CJD this prompted 
comprehensive measures aiming at the prevention of iatro-
genic prion transmissions to humans. An important element 
of these measures are the specifically devised safety guide-
lines on the reprocessing of surgical, diagnostic or other 
medical devices and on the supply of blood or blood prod-
ucts with a view to CJD and vCJD [39].
Prions and Alzheimer‑ or Parkinson‑associated protein 
aggregates: commonalities and dissimilarities
Pathological protein aggregates in Alzheimer’s 
and Parkinson’s disease
The neuropathological hallmarks of AD are extracellular 
senile plaques and intraneuronal neurofibrillary tangles 
(NFT) primarily composed of aggregated amyloid-β [Aβ, 
Fig. 1  Mechanistic model of prion formation and replication by 
nucleation-dependent aggregation of the prion protein. The prion pro-
tein (PrP) can adopt different spatial structures. Cellular prion protein 
(PrPC) has a relatively high content of α-helical structure elements 
but may convert into isoforms with an aberrant conformation. Under 
certain conditions those PrP conformers can assemble into β-sheet-
rich aggregates that constitute self-replicative proteinaceous infec-
tious particles (prions). The misfolded and aggregated PrP in prions 
is referred to as PrPTSE. Primary seed formation, or nucleation, of PrP 
underlying the initial formation of prions in sporadic or hereditary 
prion diseases is controlled by a high kinetic barrier. However, once 
prions have been endogenously formed, or exogenously introduced 
into the body by infection, they behave as seeds that swiftly recruit 
and attach further PrP molecules. When prions eventually fragment 
into smaller PrP aggregates, progeny seeds enter the prion replication 
cycle and further propagate the pathological protein state. The NMR 
solution structure of recombinant human prion protein hPrP(23–230) 
was reproduced, in accordance with the copyright policies of PNAS, 
from Zahn et al. [97] (copyright by PNAS). Nucleation-dependent 
protein aggregation is thought to similarly underlie the formation and 
propagation of AD- and PD-associated protein particles
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a peptide processed from the cellular amyloid precursor 
protein (APP)] and partially hyperphosphorylated tau pro-
tein, respectively [60]. In about 80 % of patients, AD is 
associated with cerebral amyloid angiopathy, i.e., deposits 
of Aβ in blood vessels of the brain [84]. Tau aggregates in 
the brain do not occur exclusively in AD, but also in other 
neurodegenerative diseases which are collectively referred 
to as tau aggregation diseases and include frontotemporal 
dementias [41].
Brains of patients with PD typically show cell loss in 
the substantia nigra (particularly in the ventral part of the 
pars compacta) and contain fibrillar protein inclusions 
in cell bodies and processes of neurons. These inclusions 
are designated as Lewy bodies and Lewy neurites, respec-
tively, and essentially consist of aggregated α-synuclein, 
a proportion of which is phosphorylated [23]. Such Lewy 
pathology also occurs in “dementia with Lewy bod-
ies” (DLB), and pathological deposits of misfolded and 
aggregated α-synuclein primarily in oligodendrocytes are 
pathognomonic of multiple system atrophy (MSA), another 
α-synuclein aggregation disease [16]. Recently, it has 
been shown that in DLB and PD most α-synuclein aggre-
gates occur in the presynapse of nerve cells [50, 81] and 
are linked with a synaptic failure [83]. It is under debate, 
whether Lewy bodies are a compartmentalization of pro-
tein aggregates to protect the cell from harmful (synaptic) 
α-synuclein aggregates [65, 82].
The deposition of pathological protein aggregates in the 
nervous system of humans with AD and PD shows partly 
stereotypic temporal–spatial spreading patterns, particu-
larly for tau and α-synuclein [12, 43, 52], which is remi-
niscent of the spreading characteristics of prions. Studies 
in animals with an experimental or natural prion infection 
have shown that the deposition of PrPTSE in the nervous 
system proceeds in highly defined temporal–spatial pat-
terns, apparently transsynaptically, along neuronal projec-
tions and circuits from initial foci to adjacent and distant 
target areas [4, 5, 90]. Accordingly, stereotypic spatiotem-
poral patterns of pathological protein deposition in AD 
and PD can be explained by the formation of initial protein 
seeds early in pathogenesis, and a subsequent prion-like 
spread of misfolding and aggregation along neuroanatomi-
cal pathways. Alternatively, protein aggregation may start 
and proceed, in a relatively uniform temporal–spatial pat-
tern, independently at different sites in the brain of AD and 
PD patients, and thereby produce the observed stereotypic 
courses [52]. The former hypothesis, however, seems to be 
supported by an observed spread of α-synuclein aggrega-
tion from affected brain tissue into fetal neuronal trans-
plants in PD patients [43], and by further findings from 
in vitro and in vivo studies described in the following 
sections.
Seeded aggregation of Aβ, tau and α-synuclein in vitro
The aggregation mechanisms of Aβ, tau and α-synuclein 
have been extensively explored in comprehensive in vitro 
studies which involved natural and recombinant protein 
forms [16]. Results from these studies indicate that the 
aggregation of Aβ, tau and α-synuclein occurs by a mecha-
nism of nucleated growth which basically resembles that of 
PrP aggregation. However, it is still unclear to what extent 
AD- or PD-associated protein aggregates are self-propagat-
ing in a prion-like manner, i.e., how efficiently they fragment 
into progeny seeds, and how efficiently such progeny seeds 
then replicate in further cycles of growth and fragmentation.
During the past few years, it has become possible to 
mimic an indefinite self-perpetuation of the seeded aggrega-
tion of PrP (which is accompanied by a replication of infec-
tivity) in vitro using cell-free serial protein misfolding cyclic 
amplification (sPMCA) [6, 13, 79, 93]. This technique repro-
duces putative key steps of prion replication in an accelerated 
manner in the test tube, and demonstrated the auto-seeding 
activity of newly generated PrP aggregates in multiple serial 
passages (i.e., after the initial seeding material had been suc-
cessively diluted out). A similar, virtually indefinite, self-
perpetuation of protein aggregation in cell-free conversion 
assays has not been shown so far for Aβ and tau aggregates, 
but was recently reported for α-synuclein based on findings 
in PMCA and aggregation assays that used in vitro generated 
fibrillar α-synuclein as seeding material [38, 77].
In cell assays, AD- and PD-associated protein aggregates 
show similarities to prions in terms of (i) binding to or uptake 
by cells of Aβ [96], tau [28, 63] or α-synuclein aggregates 
[63, 91], (ii) seeding in or on cells of Aβ [96], tau [63, 80] 
or α-synuclein aggregates [54, 63, 91], and (iii) intercellular 
spread of tau [28] and α-synuclein deposition [34]. In contrast 
with prions, aggregated Aβ and α-synuclein species have not 
yet been reported to show sustained self-propagation in mul-
tiple serial cell culture passages. However, Sanders et al. [80] 
recently demonstrated that different species of aggregated tau 
templated themselves with high fidelity through serial pas-
sages of HEK cell lines that stably expressed the aggregation-
competent repeat domain of this protein.
The fact that AD- and PD-associated protein particles 
share nucleation-dependent protein aggregation as the 
molecular mechanism of their origin and other properties 
with prions, but not the latter’s obvious infectiousness (i.e., 
communicability or even contagiousness), is reflected in 
the term “prionoid” that has been introduced to designate 
prion-like seeding-active forms of Aβ, tau or α-synuclein 
[1, 2]. A substantial body of data obtained during the past 
few years [12, 32, 43, 52] has raised the question as to what 
extent Aβ-, tau- or α-synuclein aggregates behave like pri-
ons—and whether they can possibly transmit disease.
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Experimental transmission of Aβ-, tau- or α-synuclein 
aggregates to laboratory animals
Fatal prion infections can be experimentally transmit-
ted from affected individuals to laboratory animals. Sub-
sequently, they can be further passaged, in principle 
indefinitely, in vivo. During the past few years, similarly 
designed animal experiments have been increasingly per-
formed to examine whether protein aggregation, neurode-
generation or clinical disease can result from an in vivo 
transmission of sample materials containing Aβ-, tau- or 
α-synuclein aggregates. In the following text, such sample 
materials are designated as “Aβ, tau or α-synuclein inoc-
ula”, or as “Aβ”, “tau” or “α-synuclein” with subscripted 
indices to indicate the origin of the respective inoculum.
For the experimental transmission of Aβ-, tau- or 
α-synuclein inocula, different types of wild-type animals 
were used, as well as transgenic rodents that homo-, hetero- 
or hemizygously expressed normal or mutated human APP-, 
tau- or α-synuclein. The mutated protein variants were asso-
ciated with familial forms of AD, frontotemporal dementia, 
or PD. Many transgenic models used in these transmission 
studies showed a considerable overexpression of the respec-
tive proteins. A proportion (but not all) of the transgenic 
rodent models developed during their natural lifespan a con-
genital phenotype with (i) protein aggregation detectable in 
the CNS as Aβ deposits, inclusions of filamentous or NFT-
like tau, or accumulations of α-synuclein, (ii) neurodegen-
eration in the CNS, and/or (iii) cognitive or neurological 
symptoms. Among the rodents challenged with Aβ-, tau- or 
α-synuclein inocula were the following animals (for study 
design, references and results see Table 1):
•	 Transgenic mice expressing mutated forms of human
	– APP (Tg2576 mice; APP23 mice; APP23:Gfap-luc 
mice; APPSwe/PSENΔE9 mice; APPPS1 mice),
	– tau (B6/P301L mice; P301S mice; P301S PS19 
mice), or
	– α-synuclein (homozygous A53T M83+/+ mice, Fig. 2)
 that developed during their natural lifespan Aβ-, tau- or 
α-synuclein aggregates in the CNS, respectively. P301S 
PS19 and M83+/+ mice also developed neurodegenera-
tion as well as severe motor dysfunction and fatal neuro-
logical disease.
•	 Transgenic mice hemizygously expressing mutated 
human α-synuclein (A53T M83+/−: Gfap-luc mice) 
which were reported to show no protein aggregation or 
clinical disease until at least 629 days of age. It is, how-
ever, currently unclear whether these mice may develop 
protein aggregates, neurodegeneration or clinical dis-
ease at higher ages.
•	 Transgenic mice expressing normal forms of human 
APP (HuAPPwt mice) or tau (ALZ17 mice), and trans-
genic rats expressing a mutated form of human APP 
(APP21 rats). These transgenic rodent models did 
not show protein aggregates in the CNS during their 
(median) natural lifespan.
•	 Wild-type (wt) mice.
Fig. 2  Congenital phenotype of cerebral α-synuclein aggrega-
tion in TgM83+/+ mice used for transmission studies with differ-
ent α-synuclein inocula. TgM83+/+ mice expressing human A53T 
mutated α-synuclein begin to show α-synuclein aggregates in the 
CNS from an age of about 8 months. At the same age, few TgM83+/+ 
mice display signs of neurodegeneration and onset of eventually fatal 
motor dysfunction. The percentage of neuropathologically and clini-
cally affected mice increases with age, and by 16 months of age all 
mice have developed the described phenotype [30]. The photomicro-
graphs show pathological α-synuclein deposits in cerebral perikarya 
(a, arrows) and neurites (b, arrowheads) of a female TgM83+/+ 
mouse at an age of 257 days [immunostaining was performed using 
an anti-alpha-synuclein (phospho S129) antibody (ab51253; Abcam, 
Cambridge, UK)]. Using this mouse model, different studies were 
able to demonstrate that i.c. injected inocula containing α-synuclein 
aggregates from mice or humans accelerated the occurrence of intra-
cellular α-synuclein inclusions in the CNS of the recipient animals 
[56, 62]. Additionally, these studies showed a premature onset of fatal 
disease in TgM83+/+ mice that had been challenged by i.c. injection 
of those murine inocula or fibrils that had been preformed in vitro 
from recombinant human α-synuclein
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Two important aspects have to be considered for the 
interpretation of results from transmission studies in trans-
genic animals. First, if Aβ-, tau- or α-synuclein inocula 
stimulate the formation of cerebral protein aggregates in 
transgenic mice which have a congenital phenotype of pro-
tein aggregation, this leaves basically two alternative expla-
nations: (i) that the inoculated material caused (i.e., trans-
mitted) such aggregation in the true sense, or (ii) that the 
inoculum merely increased or accelerated the pathological 
protein deposition in specific brain regions in terms of a 
quantitatively stronger or earlier occurrence, respectively. 
Accordingly, it is deemed prudent to interpret a stimulation 
of protein aggregation in such bioassay animals conserva-
tively as evidence for an “increase” or “acceleration” of the 
protein pathology [14].
Second, transgenic animals showing no congenital pro-
tein aggregation may theoretically still contain unnaturally 
high levels of different species of Aβ-, tau- or α-synuclein 
assemblies. Therefore, such mice “might be borderline with 
respect to the levels required for triggering higher-level 
aggregation. Increasing the Aβ (or tau- or α-synuclein—
author’s note) load of a particular biochemical species 
could then trigger Aβ (or tau- or α-synuclein—author’s 
note) deposits” [70]. Accordingly, the occurrence of pro-
tein deposition in those transgenic animals after a challenge 
with Aβ-, tau- or α-synuclein inocula should be interpreted 
as a “triggering” of endogenous protein deposition.
Whether Aβ-, tau- or α-synuclein inocula can genuinely 
“cause” (i.e., actually transmit) protein aggregation in vivo, 
finally, requires testing in wild-type animals.
Reported findings
Key findings from transmission experiments with Aβ-, 
tau- and α-synuclein inocula are described in the following 
paragraphs and summarized, for the studies that were per-
formed in rodents, in Table 1.
Aβ
When inocula containing Aβ aggregates from brain tissue 
of AD patients, non-demented elderly donors or transgenic 
mice with cerebral Aβ-amyloidosis (Aβhu-AD, Aβhu-nonAD, or 
Aβmu, respectively), or inocula which contained Aβ aggre-
gates that had been preformed in vitro from Aβ peptides 
(Aβpreformed) were
•	 intracerebrally injected into Tg2576- (Aβhu-AD [46]), 
APP23-(Aβhu-AD [59], Aβmu [26, 37, 59]), APP23:Gfap-
luc-(Aβmu, Aβpreformed [88]), APPSwe/PSENΔE9- (Aβhu-
nonAD [25]), APPPS1-(Aβmu [37, 59]), or B6/P301L 
mice (Aβmu [8]),
•	 intraperitoneally injected into APP23 mice (Aβmu [27]),
•	 or administered to APP23 mice by i.c. implantation of 
stainless steel wires that had been contaminated with 
Aβmu [26]
this resulted in a stimulation of the cerebral Aβ deposition 
in the recipient animals which were all congenitally pre-
disposed for protein aggregation. Specifically, an increase 
of the cerebral Aβ-burden was found in two mouse mod-
els (APP23:Gfap-luc mice injected with Aβmu or Aβpreformed 
[88], and APPSwe/PSENΔE9 mice injected with Aβhu-nonAD 
[25]), while Tg2576 mice (injected with Aβhu-AD [46]), 
APP23 mice (injected with Aβhu-AD [59] or Aβmu [26, 
37, 59]) and APPPS1 mice (injected with Aβmu [37, 59]) 
showed an acceleration of cerebral Aβ deposition.
Furthermore, the study in APP23:Gfap-luc mice dem-
onstrated that preformed Aβ aggregates were sufficient 
to stimulate Aβ deposition in vivo [88]. In B6/P301L 
mice injected with Aβmu an acceleration of the formation 
of hyperphosphorylated intraneuronal tau inclusion was 
detected [8], which was indicative of cross-seeding. Also, 
intraperitoneally administered Aβmu was found to acceler-
ate cerebral Aβ-amyloidosis [27], and increased or acceler-
ated Aβ deposition in the brain was often detected beyond 
the site of inoculation in all studies. These latter finding 
resembled to some extent prion-like spreading phenom-
ena. Finally, different morphotypes of Aβ aggregates were 
detected and differentially maintained upon inoculation 
into recipient animals [37]. Such morphotypes may provide 
yet another analogy to prions. However, the replication of 
distinct prion conformers can be maintained in vivo over 
multiple serial passages which has not been shown so far 
for Aβ.
Aliquots of Aβhu-AD were i.c. also injected into trans-
genic HuAPPwt mice [61] and APP21 rats [78] that had no 
congenital phenotype of protein aggregation. This triggered 
Aβ deposition, which would otherwise not have occurred, 
in brain tissue near the injection site, and, in HuAPPwt 
mice, also in distant brain areas.
However, none of the transmission studies with Aβ inoc-
ula provided evidence for cerebral neurodegeneration, pro-
nounced cognitive decline or development of fatal disease 
in the challenged rodent models.
Primates appear as the most suited model animals for 
assessing potential hazards of Aβ inocula due to their 
close phylogenetic relationship to humans. Monkeys 
(marmosets) that had been i.c. inoculated with brain 
homogenates from nine patients with sporadic AD and 
five patients with familial AD were found in a long-term 
study (duration >20 years) to show more frequently and 
earlier cerebral Aβ deposition than control animals [3, 
57, 76]. However, cerebral Aβ deposits also occurred in a 
proportion of control animals. In a conservative approach 
these findings would be interpreted as an indication that 
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the injected inocula accelerated Aβ amyloidosis. Whether 
a triggering or causation of cerebral Aβ deposition had 
occurred in a proportion of the challenged primates could 
not be resolved by the experiment. In any case, none of 
the challenged monkeys showed the development of neu-
rofibrillary tau deposits or AD typical signs of disease. 
The findings from this long-term study in nonhuman 
primates are consistent with the notion that cerebral Aβ 
deposits are an essential but not sufficient neuropatholog-
ical criterion for AD, and with reports that the brain of 
elderly people who are not affected by neurodegenerative 
dementias may contain substantial deposits of aggregated 
Aβ [74, 85, 86, 89].
Similarly, the inoculation of sample material from more 
than 100 cases of AD into primates at the US National 
Institutes of Health (NIH) did not result in motor or behav-
ioral abnormalities in the recipients that would have indi-
cated a transmission of disease [9]. Additionally, neuro-
pathological postmortem examinations of brain specimens 
from primates of the NIH study did not provide evidence 
for a pre- or subclinical disease transmission, according to 
a personal communication by members of the former NIH 
research team (P. Brown, D. Asher) reported by Irwin et al. 
[42]. In contrast to these negative findings with AD inoc-
ula, more than 300 cases of prion diseases were transmit-
ted to primates at the NIH during the same period of time 
[9].
Tau
The administration of inocula which had been prepared 
from brain tissue of transgenic mice with cerebral tau 
deposits (taumu) or lysates of transgenic HEK cell lines 
that propagated tau inclusions (tauHEK cells), as well as the 
administration of inocula which contained tau aggregates 
that had been preformed in vitro from recombinant tau pro-
tein (taupreformed), by
•	 i.c. injection into P301S PS19 mice (taumu and tauHEK 
cells) [80]; taupreformed [40, 80] or
•	 intraperitoneal injection into P301S mice (taumu [19])
accelerated or increased, respectively, the cerebral depo-
sition of filamentous tau. The increase of tau aggregation in 
the brain of P301S mice which had been intraperitoneally 
injected with taumu indicated a centrifugal spread of tau 
aggregates or aggregation.
In addition, taumu [17, 18] or inocula containing aggre-
gated tau from brain tissue of human patients with tau 
aggregation diseases (tauhu [18]) were intracerebrally 
injected into transgenic ALZ17 mice. This triggered the ini-
tiation and spread of filamentous tau deposition in the brain 
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tau eventually extended from the injection sites to distant, 
anatomically connected brain regions.
I.c. injection of tauhu into C57BL/6 wild-type mice 
caused inclusions of murine tau that were detected 
6 months after inoculation at the injection site and subse-
quently increased over time [18]. When purified tau oli-
gomers from AD brain tissue were intracerebrally injected 
into wild-type C57BL/6 mice, this induced widespread 
deposits of hyperphosphorylated murine tau filaments 
in the injected area and neighboring brain regions [51]. 
According to the authors of the latter study, AD-associated 
tau oligomers were thus shown to cause tau deposition in 
wild-type mice “via a mechanism reminiscent of that used 
by prions”.
Finally, serial transmission of tau seeding was observed 
in ALZ17 mice following the i.c. injection of homogenates 
prepared from ALZ17- or C57BL/6 brains that had been 
originally injected with taumu or tauhu, respectively [18]. 
Taken together, these findings suggested according to Clav-
aguera et al. [18] that “once tau aggregates have formed 
in discrete brain areas, they become self-propagating and 
spread in a prion-like manner”.
Most recently, Sanders et al. [80] reported that dis-
tinct species of tau aggregates could be stably propagated 
through multiple generations of transgenic P301S PS19 
mice. These authors concluded that tau “encodes self-cata-
lyzing conformational information that it propagates indefi-
nitely with high fidelity”.
Despite the ability of tau inocula to increase, acceler-
ate, trigger and cause tau aggregation in vivo, none of the 
transmission studies provided evidence for cerebral neu-
rodegeneration, clinical abnormalities or severe disease in 
tau-challenged mice.
α-Synuclein
When inocula containing aggregated α-synuclein from 
brain homogenates of aged TgM83+/+ mice that had 
developed cerebral protein aggregates and neurodegen-
eration as well as fatal clinical disease (α-synucleinmu) 
were i.c. injected into young asymptomatic TgM83+/+ 
mice, this accelerated the occurrence of intracellular 
α-synuclein inclusions in the brains of the recipient ani-
mals [56, 62]. The deposition of α-synuclein seemed to 
propagate through the CNS in a time-dependent manner 
along neural pathways and also occurred in the substantia 
nigra [56]. This suggested a parallel to both the “appar-
ent spread of α-synuclein deposits in the human brain” 
[44], and the propagation of prions along neuroanatomical 
projections. After i.c. injection of α-synucleinmu, recipi-
ent animals eventually showed a reduction of tyrosine 
hydroxylase staining in nigral neurons with α-synuclein 
inclusions (suggesting impaired dopamine production in 
these cells) [56]. Additionally, TgM83+/+ mice that had 
been inoculated with α-synucleinmu showed an accelerated 
development of severe motor dysfunction and premature 
death [56, 62]. After i.c. injection of inocula containing 
fibrils that had been preformed in vitro from recombinant 
human α-synuclein (α-synucleinpreformed/hu), similar results 
were found in TgM83+/+ mice with respect to accelerated 
α-synuclein aggregation and premature onset of clinical 
disease [56].
Recently, Watts et al. [92] reported the experimental 
transmission of protein aggregation and fatal clinical dis-
ease for multiple system atrophy (MSA), an α-synuclein 
aggregation disease with α-synuclein inclusions in oli-
godendrocytes. In this study, inocula containing human 
α-synuclein aggregates from brain homogenates of MSA 
patients (α-synucleinhu-MSA) were intracerebrally injected 
into M83+/−: Gfap-luc mice [92]. Control M83+/−: Gfap-
luc mice that had not been i.c. injected with α-synucleinhu-
MSA showed no protein aggregation or clinical disease 
(neurodegeneration was not examined) until at least 
629 days of age. However, it is currently unclear whether 
such control mice may have developed a congenital phe-
notype of protein aggregation in the CNS and clinical 
disease at higher ages. Hemizygous TgM83+/− mice that 
do not carry the Gfap-luc transgene develop pathological 
α-synuclein deposition in the CNS at 22–28 months of 
age. At the same age (660–840 days), many TgM83+/− 
mice also develop the disease phenotype of homozygous 
TgM83+/+ mice [30]. Thus, a prudent approach would 
take the data reported by Watts et al. [92] either as an 
acceleration, or—if the absence of protein aggregation and 
clinical disease were shown to persist in M83+/−: Gfap-luc 
control mice during their natural lifespan—as a triggering 
of protein aggregation and clinical disease by the injected 
α-synucleinhu-MSA.
In another study, inocula containing two types of pre-
formed fibrils produced in vitro from recombinant, C-ter-
minally truncated human α-synuclein (α-synucleinpreform
ed/hu) were intracerebrally injected into transgenic P301S 
PS19 mice [33]. While one type of the fibrils substantially 
accelerated cerebral tau deposition, possibly by cross-
seeding, the other type of fibrils was much less able to do 
so. The two types of fibrils apparently represented distinct 
conformers of aggregated α-synuclein, and their different 
effects in terms of the stimulation of tau aggregation may 
be indicative of analogies to phenomena observed in the 
context of prion strains or prion types.
Furthermore, inocula containing fibrils that had been 
preformed in vitro from recombinant murine or human 
α-synuclein (α-synucleinpreformed/mu and α-synucleinprefor
med/hu, respectively), and inocula containing α-synuclein 
aggregates from enriched extracts of brain tissue from a 
patient with DLB (α-synucleinhu-DLB) or from patients 
472 Acta Neuropathol (2014) 128:463–476
1 3
with PD (α-synucleinhu-PD) caused cerebral deposi-
tion of endogenous α-synuclein in different types of 
C57BL6 wild-type mice after injection into the striatum 
(α-synucleinpreformed/mu [55]) or administration to the sub-
stantia nigra (α-synucleinpreformed/mu, α-synucleinpreformed/hu, 
α-synucleinhu-DLB [58] and α-synucleinhu-PD [75]). The sub-
sequent spread of α-synuclein deposition seemed to follow 
neuronal connections and circuits. While the three studies 
in wild-type mice by Luk et al. [55], Masuda-Suzukake 
et al. [58] and Recasens et al. [75] produced similar results 
in these respects, they partly differed with regard to the 
occurrence of neurodegeneration and clinical abnormalities 
in the challenged animals.
Luk et al. [55] observed in their study a gradual loss of 
tyrosine hydroxylase immunoreactivity and neurons in the 
substantia nigra pars compacta, and reduced striatal dopa-
mine levels in the injected hemisphere. This was accom-
panied by a performance deterioration in rotarod tests 
(latency to fall: ~200 s for α-synucleinpreformed/mu-injected 
animals vs. ~325 s for control animals), and a poorer per-
formance in wire-hang tests. However, gross motor or 
behavioral abnormalities were not observed, and overall 
motor activity was not significantly altered. In the study 
by Recasens et al. [75] the i.c. injection of α-synucleinhu-
PD caused a progressive nigrostriatal dopaminergic neuro-
degeneration. At 4 months post-inoculation these authors 
observed impaired motor ability when mice were exam-
ined in the pole test which measures motor coordination 
and balance. Yet, again, no gross motor or behavioral 
abnormalities were observed up to 17 months post-inocu-
lation. Finally, Masuda-Suzukake et al. [58] reported find-
ings suggesting that dopaminergic neurons were retained 
in the substantia nigra after injection of α-synucleinprefo
rmed/hu, while they observed a prominent reduction of the 
neurotransmitter enkephalin in some brain regions. In the 
study by Masuda-Suzukake et al. [58], no significant dif-
ferences were observed in rotarod- or wire-hang tests 
between α-synucleinpreformed/hu-injected and control mice 
at 6 months post-inoculation. At this time-point prominent 
cerebral α-syuclein deposition was already detectable in 
α-synucleinpreformed/hu-injected mice.
Despite these partly divergent results, the studies by 
Luk et al. [55], Masuda-Suzukake et al. [58] and Recasens 
et al. [75] consistently failed to detect typical PD symp-
toms (such as tremor, rigor, slowness of movement or pos-
tural instability) in wild-type mice after the transmission of 
α-synuclein inocula.
Recasens et al. [58] also injected α-synucleinhu-PD 
into the striatum or substantia nigra of rhesus monkeys. 
Striatal inoculation produced a widespread increase of 
α-synuclein immunolabeling and also an increase of phos-
phorylated α-synuclein species in the brain, while injec-
tion into the substantia nigra essentially resulted in diffuse 
local intracellular accumulations of α-synuclein. These 
α-synuclein pathologies were accompanied by a slowly 
progressing dopaminergic nigrostriatal neurodegeneration. 
At 14 months post-inoculation, when the study was termi-
nated, the α-synucleinhu-PD-injected monkeys showed nei-
ther behavioral changes nor signs of clinical disease.
When samples from 24 cases of PD with dementia were 
inoculated into primates at the NIH, this produced exclu-
sively negative results. The challenged primates did not 
show clinical signs of disease transmission [9]. Neuro-
pathological postmortem examinations also failed to reveal 
indications for a pre- or subclinical disease transmission 
according to a personal communication by members of the 
former NIH research team (P. Brown, D. Asher) reported 
by Irwin et al. [42].
Epidemiological studies on the transmissibility 
of Alzheimer’s and Parkinson’s disease
Available epidemiological data do not provide indications 
that transmission of AD or PD between humans occurs in 
real life. Observational and cohort studies failed to iden-
tify sufficient evidence for firm conclusions on the asso-
ciation of any modifiable risk factors for the development 
of AD [24, 69]. A limited number of studies specifically 
examined the epidemiological association between AD and 
blood transfusions. Findings of a study by Kokmen et al. 
[49] suggested that blood transfusions do not constitute 
a risk factor for AD in transfusion recipients. Two case–
control studies by O´Meara et al. [64] and Bohnen et al. 
[7] which examined more than 550 cases and correspond-
ing controls also did not find an association between blood 
transfusions and AD. This result was not influenced by the 
latency period between transfusion and occurrence of AD 
in transfusions recipients, the recipient’s apolipoprotein 
E epsilon 4 (APOE-e4) status, or the number of received 
transfusions. Finally, an epidemiological analysis in the 
United Kingdom of the causes of death of more than 6,000 
hemophiliacs who had received blood products via plasma 
protein therapy throughout their whole life did not detect 
an elevated level of diseases of the nervous system in this 
group of patients [22].
A recent study by Irwin et al. [42] examined the risk 
of AD or PD transmission in recipients of cadaveric 
human growth hormone that had been prepared from the 
pituitary gland of deceased donors. Medical treatments 
with c-hGH caused more than 200 cases of iatrogenic 
Creutzfeldt–Jakob disease (iCJD) worldwide due to inad-
vertent contamination with infectious PrPTSE seeds (i. e. 
prions) from donors who pre- or subclinically had incu-
bated a prion disease [11]. Against this background, Iwrin 
et al. analyzed whether AD or PD occurred, similarly 
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to iCJD, more frequently in recipients of c-hGH than in 
control persons. The authors reported that they found 
mild amounts of aggregated Aβ-, tau- and α-synuclein 
in the pituitary glands of normal individuals as well as 
of patients with neurodegenerative diseases. At the same 
time, the incidence of PD and AD exceeds that of human 
prion diseases in the general population (and thus prob-
ably also in c-hGH donors) by more than two or three 
orders of magnitude, respectively. Accordingly, recipients 
of c-hGH should have been exposed to potentially seed-
ing-active Aβ-, tau- or α-synuclein particles with a much 
higher likelihood than to prions, provided that AD- or 
PD-associated protein particles passed like PrPTSE seeds 
through the extraction procedure of c-hGH. Yet, Irwin 
et al. found in their epidemiological analysis that of 796 
deceased c-hGH recipients none had developed AD or PD 
(mean age at death: 27.2 years [range 0–77 years]; mean 
duration from first treatment to death: 16.3 years [range 
0–45 years]). Basically, this finding suggested two alter-
native conclusions: (i) That AD- or PD-associated protein 
particles were present in c-hGH but not able to transmit 
AD or PD to the hormone recipients, or (ii) that Aβ-, tau- 
or α-synuclein aggregates were more effectively removed 
or inactivated by the procedure for c-hGH purification 
than PrPTSE seeds. In any case, no indications for a prion-
like disease transmission by Aβ-, tau- or α-synuclein 
aggregates were detected in recipients of c-hGH, a 
group of patients that provide a “unique in vivo model of 
human-to-human transmission” [42].
Discussion
Transmission studies in animals
A substantial body of experimental data shows that 
the administration of inocula containing Aβ-, tau- or 
α-synuclein aggregates of animal, human or in vitro ori-
gin can increase, accelerate, trigger or cause the cerebral 
aggregation and deposition of endogenous Aβ-, tau- and 
α-synuclein in laboratory animals. As to the negative find-
ings that have been published [9] or otherwise communi-
cated [42] from the NIH’s primate study it should be noted 
that these experiments were performed before the mod-
ern tools to analyze neuropathological lesions of AD and 
PD were available. Thus, it appears tempting to speculate 
whether a re-examination of brain tissue specimens from 
these studies using current tools and antibodies (if possible 
at all) would, or would not, reveal the transmission of AD- 
or PD-like protein aggregation.
In contrast to the efficient stimulation of protein aggre-
gation in vivo by Aβ-, tau- and α-synuclein inocula these 
sample materials have not been found to transmit severe 
or fatal diseases after i.c. injection into rodents and pri-
mates. Thus, in terms of disease transmission Aβ-, tau- 
and α-synuclein particles seem to fundamentally differ 
from prions. However, the failure to detect any transmis-
sion of a severe cognitive or neurological disease after 
i.c. injection of Aβ-, tau- and α-synuclein inocula may be 
due to the inability of the used animal models to repro-
duce cardinal symptoms of complex human neurodegen-
erative diseases such as AD or PD. Additionally, many 
transgenic mouse models were primarily engineered for 
the purpose of developing morphologically identifiable 
Aβ-, tau- or α-synuclein aggregates. Those mouse mod-
els often do not show significant CNS neurodegenera-
tion (in proportion to the burden of protein aggregates), 
and whether they represent models of disease as opposed 
to protein aggregation is unclear. Although such trans-
genic models can be very sensitive to protein seeding by 
injected Aβ-, tau- or α-synuclein samples they may be 
rather insensitive to clinical disease transmission. In con-
trast to such transgenic mouse models of neuropathologi-
cal AD or PD features, PrP transgenic mice were often 
specifically designed to increase the susceptibility to 
prion infections. This potential caveat has to be consid-
ered for AD or PD transmission studies in transgenic ani-
mals but does not apply to wild-type rodents or primates. 
Still, transmission studies in these latter animals also 
revealed a conspicuous discrepancy between efficient 
experimental acceleration (by Aβ inocula) or transmis-
sion (by tau- and α-synuclein inocula) of protein aggre-
gation, and a lack of concomitant acceleration or trans-
mission, respectively, of severe cognitive or neurological 
disease. Thus, the consistently failed disease transmis-
sions by Aβ-, tau- and α-synuclein inocula observed so 
far may suggest an alternative conclusion: That Aβ-, 
tau- and α-synuclein aggregates, also when being seed-
ing-active and partly able to produce neurotoxic effects, 
cannot transmit neurodegenerative diseases such as AD 
or PD.
In any case, the seeding effects that Aβ-, tau- or 
α-synuclein inocula have been shown to exert on endoge-
nous proteins of laboratory animals have raised concerns of 
potential infectiological risks. A transfer of AD or PD pro-
tein particles between humans could hypothetically occur 
via contaminated and insufficiently reprocessed surgical 
instruments, or via blood or blood products.
Epidemiological studies
Epidemiological studies can help to assess whether there 
are tangible risks for the transmission of AD or PD under 
real-life conditions. Available data from such studies do not 
provide indications for the transmissibility or transmission 
of AD or PD between humans via blood, blood products 
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or other routes. However, AD and PD have a much higher 
prevalence than human prion diseases, and the interpreta-
tion of epidemiological studies on highly prevalent and 
multifactorial diseases such as AD and PD is complicated. 
Therefore, it may be difficult to epidemiologically track 
down any infectious origin if such cause underlay a sub-
group of AD or PD cases.
Conclusion and outlook
So far, neither experimental nor epidemiological studies 
provided evidence for a transmission of severe or even fatal 
disease by AD- or PD-associated protein particles. How-
ever, in the light of findings in TgM83 mice [56, 62, 92] 
it appears conceivable that exogenous α-synuclein seeds 
may accelerate the pathogenesis of genetically predisposed 
α-synuclein aggregation diseases. Furthermore, inocula 
that contained α-synuclein aggregates caused neurotoxic 
effects and neurological impairments in some studies with 
wild-type mice [55, 75]. Thus, a thorough decontamina-
tion of surgical instruments and other medical devices from 
aggregated Aβ-, tau- and α-synuclein by effective and rou-
tinely applicable reprocessing procedures may possibly add 
to patient safety. In contrast, the current data reviewed in 
this article do not suggest specific precautionary measures 
for hemotherapy.
Certainly, further epidemiological and experimental 
research is necessary to clarify the hazards possibly ema-
nating from transmissible Aβ-, tau- or α-synuclein seeds 
in more depth. Yet, for the time being, prions of transmis-
sible spongiform encephalopathies seem to remain unique 
pathogens.
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